Akhmetzianov R V, Bredikhin R A
Interregional Clinical and Diagnostic Centre, Kazan, Russia; Course of Cardiovascular Surgery of the Kazan State Medical University, Kazan, Russia.
Angiol Sosud Khir. 2018;24(2):93-99.
Presented herein are the results of using Detralex in conservative treatment of women suffering from pelvic varicose veins. Our open prospective study included a total of 30 women with various forms of the course of the disease. All patients took Detralex prescribed at a daily dose of 1,000 mg for 60 days. Dynamic assessment of clinical manifestations of pelvic varicose veins in this cohort of patients was carried out with the help of a specialized quality-of-life questionnaire, an adapted clinical scale of determining disease severity, as well as a visual analogue scale for assessment of the main symptoms of the disease manifestations. The questionnaires and scales were filled in before the beginning of taking the drug and immediately after stopping it. The obtained findings objectively confirmed efficacy of conservative therapy in the majority of the responders. Reported was a decrease in the average index of quality of life from 46.77±13.25 to 36.87±8.53 points (p=0.001). The mean score of the clinical scale of disease severity regressed from 10.8±5.06 to 6.97±3.9 points (p=0.002). The average composite score for the degree of the main symptoms of the disease according to the visual analogue scale decreased from 32.9±21.26 to 19.16±16.04 points (p=0.006). We observed a dramatic decrease in severity of manifestations of the main clinical symptoms and improvement of quality of life of women on the background of taking the drug, thus suggesting its efficacy for the pathological condition concerned. The obtained results make it possible to recommend routine prescription of Detralex to all women with detected pelvic varicose veins as one of the main components of basic pharmacotherapy.
本文介绍了使用Detralex对患有盆腔静脉曲张的女性进行保守治疗的结果。我们的开放性前瞻性研究共纳入了30例患有不同病程形式疾病的女性。所有患者均服用每日剂量为1000mg的Detralex，持续60天。借助专门的生活质量问卷、用于确定疾病严重程度的适应性临床量表以及用于评估疾病表现主要症状的视觉模拟量表，对该组患者盆腔静脉曲张的临床表现进行动态评估。这些问卷和量表在开始服药前及停药后立即填写。所获得的结果客观地证实了保守治疗对大多数有反应者的有效性。报告显示生活质量平均指数从46.77±13.25降至36.87±8.53分（p = 0.001）。疾病严重程度临床量表的平均得分从10.8±5.06降至6.97±3.9分（p = 0.002）。根据视觉模拟量表，疾病主要症状程度的平均综合得分从32.9±21.26降至19.16±16.04分（p = 0.006）。我们观察到在服药期间，主要临床症状的表现严重程度显著降低，女性生活质量得到改善，这表明该药对相关病理状况有效。所获得的结果使得可以推荐对所有检测出盆腔静脉曲张的女性常规开具Detralex，作为基础药物治疗的主要组成部分之一。
